40,926 Shares in Kenvue Inc. $KVUE Purchased by FORA Capital LLC

Key Points

• FORA Capital LLC has acquired a $981,000 stake in Kenvue Inc., purchasing 40,926 shares in the first quarter of the year.
• Research firms have mixed opinions on Kenvue, with Barclays lowering the target price from $23.00 to $22.00 while five analysts rated the stock as a "Buy".
• Kenvue has announced an increase in its quarterly dividend to $0.2075 per share, representing an annualized yield of 4.0%.

FORA Capital LLC bought a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 40,926 shares of the company's stock, valued at approximately $981,000.

Several other hedge funds and other institutional investors have also bought and sold shares of KVUE. Coldstream Capital Management Inc. boosted its stake in Kenvue by 2.5% during the 4th quarter. Coldstream Capital Management Inc. now owns 26,673 shares of the company's stock worth $569,000 after acquiring an additional 656 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Kenvue by 4.5% in the fourth quarter. The Manufacturers Life Insurance Company now owns 2,235,116 shares of the company's stock valued at $47,720,000 after buying an additional 96,540 shares in the last quarter. Northern Trust Corp lifted its stake in Kenvue by 15.4% in the fourth quarter. Northern Trust Corp now owns 20,948,704 shares of the company's stock valued at $447,255,000 after buying an additional 2,796,306 shares in the last quarter. Boyar Asset Management Inc. lifted its stake in Kenvue by 2.4% in the fourth quarter. Boyar Asset Management Inc. now owns 29,876 shares of the company's stock valued at $638,000 after buying an additional 705 shares in the last quarter. Finally, One68 Global Capital LLC bought a new position in Kenvue in the fourth quarter valued at approximately $661,000. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.18 on Monday, hitting $20.72. The company had a trading volume of 10,307,391 shares, compared to its average volume of 17,119,262. Kenvue Inc. has a 1-year low of $19.75 and a 1-year high of $25.17. The stock has a market cap of $39.76 billion, a price-to-earnings ratio of 27.99, a P/E/G ratio of 2.97 and a beta of 0.83. The stock has a 50 day moving average price of $21.46 and a 200 day moving average price of $22.45. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. During the same period in the previous year, the company earned $0.32 earnings per share. The company's quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.0%. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. Kenvue's dividend payout ratio is currently 112.16%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Bank of America cut their price target on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday, July 15th. UBS Group lowered their target price on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a report on Thursday, July 17th. Zacks Research upgraded shares of Kenvue to a "strong sell" rating in a report on Monday, August 11th. Citigroup lowered their target price on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a report on Tuesday, July 15th. Finally, Royal Bank Of Canada lowered their target price on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a report on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $24.38.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.